Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003005 · ClinicalTrials.gov registry record · Phase 1
Chemotherapy With Cordycepin Plus Pentostatin in Treating Patients With Refractory Acute Lymphocytic or Chronic Myelogenous Leukemia
A Phase 1 study, sponsored by Boston Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00003005 is a Phase 1 study that has completed, run by Boston Medical Center. The registered enrollment target is 14 participants.
The verdict
NCT00003005, a Phase 1 study, has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of chemotherapy consisting of cordycepin plus pentostatin in treating patients with refractory acute lymphocytic or chronic myelogenous leukemia.
Interventions
- DRUG Cordycepin
- DRUG Deoxycoformycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 1997-12 |
| Est. Completion | 2001-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003005
The ClinicalTrials.gov registry entry for NCT00003005 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cordycepin is the first listed.
NCT00003005 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003005 about?
NCT00003005 is a clinical study titled "Chemotherapy With Cordycepin Plus Pentostatin in Treating Patients With Refractory Acute Lymphocytic or Chronic Myelogenous Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of chemotherapy consisting of cordycepin plus pentostatin in treating pat...
What is the current status of trial NCT00003005?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 1997-12. Estimated completion is 2001-03.
What interventions are being tested in trial NCT00003005?
The interventions under investigation include: Cordycepin (DRUG), Deoxycoformycin (DRUG).
Who is sponsoring clinical trial NCT00003005?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.